CEST MRI to contrast chondrosarcoma tumors: two contrasts in one acquisition

Leslie Mazuel, A. Voissiere, Valérie Weber, Yvain Gerard, Sophie Besse, J.-M. Bonny, Elisabeth Miot-Noirault, C. Peyrode, Guilhem Pages

JOINT ANNUAL MEETING
ISMRM–ESMRMB
16–21 June 2018

SMRT 27th Annual Meeting 15–18 June 2018
www.smrt.org

Paris Expo Porte de Versailles
Paris, France

Declaration of Financial Interests or Relationships

Speaker Name: Leslie MAZUEL

I have no financial interests or relationships to disclose with regard to the subject matter of this presentation.

CEST MRI to contrast chondrosarcoma tumors: two contrasts in one acquisition

L. Mazuel[1, 2], R. Autissier[1, 2], E. Maubert[1], V. Weber[1], J. M. Bonny[2] , E. Miot-Noirault[1] , C. Peyrode[1] , G. Pages[2]

[1] *INSERM, UMR1240, Clermont-ferrand, France*
[2]*AgroResonance, UR370 QuaPA-INRA, F-63122 Saint-Genès-Champanelle, France*

Pathological Context



Hypoxia



Proteoglycans



Chondrosarcoma

- **Malignant cartilage tumor**
- **2nd bone cancer**
- **Diagnostic by imaging**
  - ☜
    - no specific method
- 2 mains characteristics :
  - Hypoxia

Could be used to develop a new imaging strategy?

CEST MRI principle



Functions	Frequency
Hydroxyl (OH)	250 - 750 Hz
Amines (NH_2)	800 – 1400 Hz
Amides (NH)	1500 – 2100 Hz

APT CEST

GAG CEST

Hypoxia



Proteoglycan



CEST-MRI should be able to simultaneously image both properties

In vivo study – Experimental design

H-EMC-SS Model

3M cells H-EMC-SS
Implanted orthotopically (tibia)

Human Chondrosarcoma

> 4 weeks

Swarm Model

Swarm tumor implanted sub-cutaneously

Rat Chondrosarcoma

2 weeks

CEST MRI

Reference imaging

PET	SPECT	MRI
^{18}F-MISO	^{99m}Tc-NTP 15-5	^{23}Na

Hypoxia



Proteoglycans



CEST MRI *in vitro*

Hypoxia





↗ pH = ↗ CEST effect





Creatin
e

What happens *in vivo*?

Proteoglycans





Chondroitin 4 sulfate



↗ PG = ↗ CEST effect



PET *vs* CEST MRI

^{18}F-FMISO



T/M ratio = 1,79

T/M ratio = 2,04

The two models are hypoxic

CEST Maps



Difference in CEST effect observed in the two different models => difference in pH

SPECT *vs* CEST MRI

^{99m}Tc-NTP 15-5



CEST Maps



CEST is able to assess proteoglycans content

in different tumor model





Conclusion - Perspectives



New diagnostic tool for chondrosarcoma

Therapeutic efficiency
=> pronostic tool?